Premium
High affinity of anti‐GM 1 antibodies is associated with disease onset in experimental neuropathy
Author(s) -
Comín Romina,
Yuki Nobuhiro,
Lopez Pablo H.H.,
Nores Gustavo A.
Publication year - 2006
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.21004
Subject(s) - antibody , disease , immunology , antigen , titer , population , affinity chromatography , immunization , microbiology and biotechnology , medicine , chemistry , biology , biochemistry , enzyme , environmental health
Abstract High antibody affinity has been proposed as a disease determinant factor in neuropathies associated with anti‐GM 1 antibodies. An experimental model of Guillain‐Barré syndrome, induced by immunization of rabbits with bovine brain gangliosides or GM 1 , was described recently (Yuki et al. [2001] Ann. Neurol. 49:712–720). We searched plasma from these rabbits, taken at disease onset and 1 or 2 weeks prior to onset, for the presence of high‐affinity anti‐GM 1 IgG antibodies. Affinity was estimated by soluble antigen binding inhibition. High‐affinity antibodies (binding inhibition by 10 –9 M GM 1 ) were detected at disease onset but not before. No such difference was found for other antibody parameters such as titer, fine specificity, and population distribution. These findings support the proposed role of high affinity as an important factor in disease induction by anti‐GM 1 antibodies. © 2006 Wiley‐Liss, Inc.